 |
|
|
||||||||||||||
 |
|
|
Tethys unveils advanced-warning test for diabetes by Michael Fitzhugh
2008-Jul-02 — Tethys Bioscience Inc. is launching a new test that can identify people at high risk of developing Type 2 diabetes within five years - allowing them to take steps to reduce their risk.
Averting even a fraction of diabetes cases could help businesses put a dent in the $58 billion of indirect costs they bore in 2007 from diabetes-related absenteeism, productivity losses, disability expenses and early mortality, according to the American Diabetes Association. The company's analysis predicts the test could head off more than $11,200 in diabetes care costs per patient over 10 years.
Read the full story here.< Back
Jul 22, 2010
Tethys Raises $33 Million
Tethys Bioscience, Inc., announced today that the company has recently raised $33 million, comprising $23 million of venture financing and a $10 million working capital loan.
Jul 14, 2010
Diabetes Risk, on a Scale of 1 to 10
A new test is transforming the way some doctors diagnose and treat their patients.
(Technology Review)
Jul 1, 2010
PreDx® featured on CBS Interactive's Smartplanet
CBS Interactive smartplanet video segment focuses on the impact of the PreDx® Diabetes Risk Score on the physician and patient.
Jun 24, 2010
Tethys Announces Issuance of Key Patent Relating to PreDx™ Diabetes Risk Score Test
United States Patent and Trademark Office grants patent to Tethys. The patent is directed to the company's groundbreaking PreDx™ Diabetes Risk Score (DRS) test and relates to proprietary methods for assessing the risk of developing a diabetic condition.
Nov 9, 2009
Tethys Bioscience Raises $25 Million in Series D Financing
The financing round is led by aeris Capital with George Rehm taking a seat on the Tethys board.
Oct 20, 2009
Gazing into the Future
(Journal of Life Sciences, Fall 2009)